Carcinoma, Non-Small-Cell Lung — Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Citation(s)
A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)